Publications by authors named "R Sellar"

Claim this Profile
C
CPX-351 versus daunorubicin, cytarabine plus gemtuzumab ozogamicin in older adults with non-adverse risk AML: NCRI AML18.
Steven Knapper, Laura W Dillon, Malavika Babu, Abin Thomas, Ian Thomas, Rob S Sellar

Blood· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment Intensification With Either Fludarabine, AraC, G-CSF and Idarubicin, or Cladribine Plus Daunorubicin and AraC on the Basis of Residual Disease Status in Older Patients With AML: Results From the NCRI AML18 Trial.
Nigel H Russell, Abin Thomas, Robert K Hills, Ian Thomas, Amanda Gilkes, Rob S Sellar

J Clin Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.
Jad Othman, Angela Hwang, Maximillian Brodermann, Islam Abdallah, Kayleigh McCloskey, Rob Sellar

Blood Adv· November 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The clonal hematopoiesis mutation Jak2 aggravates endothelial injury and thrombosis in arteries with erosion-like intimas.
Roberto Molinaro, Rob S Sellar, Amélie Vromman, Grasiele Sausen, Eduardo Folco

Int J Cardiol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The emerging role of targeted protein degradation to treat and study cancer.
Maximillian H Brodermann, Elizabeth K Henderson, Rob S Sellar

J Pathol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis